Lexaria Bioscience (LXRP) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free LXRP Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLexaria gets ethics board okay for oral GLP-1 studymsn.com - April 16 at 3:35 PMLexaria (NASDAQ: LEXX) Hires Research Organization to Perform GLP-1 Human Pilot Studytheglobeandmail.com - March 27 at 9:50 AMLexaria appoints Nelson Cabatuan as CFOmsn.com - March 14 at 12:59 PMLexaria Bioscience (NASDAQ: LEXX) Banking on DehydraTECH(TM) for Major 2024 Growththeglobeandmail.com - March 11 at 12:04 PMLexaria Bioscience Corp.: Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinanznachrichten.de - February 16 at 6:06 PMWhy Lexaria Bioscience (LEXX) Shares Are Movingmsn.com - February 15 at 12:03 PMLexaria Unveils Extensive Planned 2024 GLP-1 Study Programfinance.yahoo.com - January 16 at 9:48 AMLexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstreamfinance.yahoo.com - January 11 at 8:53 AMLEXX: GLP-1s’ Sweet Opportunitymsn.com - November 30 at 1:27 PMLexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Spacefinance.yahoo.com - November 1 at 9:17 AMLexaria Bioscience’s Growth Prospects: New Licensing Agreement, Advanced Core Pipeline, and Positive Clinical Trialsmarkets.businessinsider.com - October 18 at 7:59 PMLexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSynfinance.yahoo.com - October 13 at 10:35 AMLexaria Bioscience (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery Sectormsn.com - August 5 at 8:21 PMLexaria Bioscience Corp.: Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBDfinanznachrichten.de - August 2 at 9:39 AMLexaria Bioscience (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine Studytheglobeandmail.com - July 29 at 2:55 AMLexaria Bioscience Corp.: Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Studyfinanznachrichten.de - July 28 at 11:53 AMLexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Studyfinance.yahoo.com - July 28 at 11:53 AMLexaria Bioscience Corp.: Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Productsfinanznachrichten.de - July 19 at 10:52 AMLexaria Bioscience Corp.: Lexaria Announces 2023 Annual Meeting Resultsfinanznachrichten.de - May 10 at 11:05 AMLexaria Announces 2023 Annual Meeting Resultsfinance.yahoo.com - May 10 at 11:05 AMLexaria Bioscience (NASDAQ: LEXX) Announces Dosing Completed on Human Nicotine Studytheglobeandmail.com - May 9 at 2:57 PMWhy Is Lexaria Bioscience (LEXX) Stock Down 27% Today?investorplace.com - May 9 at 10:18 AMLexaria Bioscience Corp.: Lexaria's Human Clinical Nicotine Study Completes Dosing as Plannedfinanznachrichten.de - May 8 at 10:03 AMLexaria’s Human Clinical Nicotine Study Completes Dosing as Plannedfinance.yahoo.com - May 8 at 10:03 AMLexaria Bioscience Corp.: Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Studyfinanznachrichten.de - April 25 at 7:09 PMLexaria (NASDAQ: LEXX) Revolutionizing Delivery Potential for APIs Using DehydraTECH(TM)theglobeandmail.com - April 12 at 3:55 PMLexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBDyahoo.com - February 21 at 4:18 PMAnnual Letter from Lexaria CEO, Chris Bunka and Thorough Strategic Update to All Stakeholdersstockhouse.com - January 15 at 3:08 PMLexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canadabenzinga.com - January 13 at 10:37 AMLexaria Bioscience Corp.: Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levelsfinanznachrichten.de - December 22 at 12:44 PMLexaria Bioscience Corp.: Lexaria's Human Oral Nicotine Study Begins Dosingfinanznachrichten.de - December 20 at 12:58 PMLexaria's Human Oral Nicotine Study Begins Dosingbenzinga.com - December 20 at 12:58 PMLexaria Bioscience Turns Focus to Dementia and Diabetes with New Studiesfinance.yahoo.com - November 21 at 9:55 AMLexaria Bioscience progresses with hypertension and oral nicotine studies using DehydraTECHproactiveinvestors.com - November 3 at 11:05 PMLEXX: DehydraTECH CBD HYPER-H21-4 Resultsmsn.com - October 31 at 10:23 AMLexaria Bioscience Corp.: Lexaria's Human Clinical Hypertension Study a Successfinanznachrichten.de - October 28 at 1:41 PMLexaria Welcomes Dr. Catherine Turkel to its Board of Directorsapnews.com - September 2 at 9:53 AMTinyGemsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Discusses Biotech Industry Valuation Metricsmarketwatch.com - August 12 at 5:26 AMLexaria Bioscience Corp.: Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertensionfinanznachrichten.de - August 10 at 12:34 PMLexaria Gets FDA's Positive Feedback On Pre-Clinical Trial Of Hypertension Candidatemsn.com - August 10 at 12:34 PMLexaria’s DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Eventsapnews.com - July 27 at 4:52 PMLexaria Bioscience Corp.: Lexaria's Human Nicotine Study Nearing Start Datefinanznachrichten.de - July 15 at 1:21 AMLexaria To Receive Third Patent Granted in Japan; Submits FDA Filingapnews.com - July 14 at 10:16 AMLexaria Flat on Patent News from Japanbaystreet.ca - July 14 at 10:16 AMLexaria's Human Nicotine Study Nearing Start Datefinance.yahoo.com - July 13 at 9:39 AMLexaria Bioscience Shares Rise 17% After Two Deals With BevNologymarketwatch.com - June 21 at 5:00 PMLexaria Files Pre-IND Meeting Request Letter with U.S. FDAfinance.yahoo.com - June 6 at 11:19 AMLexaria Bioscience Corp.: Lexaria Files Pre-IND Meeting Request Letter with U.S. FDAfinanznachrichten.de - June 6 at 11:19 AMLexaria Edges up on FDA Dealbaystreet.ca - June 6 at 11:19 AMLexaria files pre-IND meeting request with FDA for its CBD-based hypertension treatmentseekingalpha.com - June 6 at 11:19 AM Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRP and its competitors with MarketBeat's FREE daily newsletter. Email Address Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> LXRP Media Mentions By Week LXRP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRP News Sentiment▼0.000.32▲Average Medical News Sentiment LXRP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRP Articles This Week▼00▲LXRP Articles Average Week Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Earth Science Tech News Today Covalon Technologies News Today Poxel News Today Streamline Health Solutions News Today Addex Therapeutics News Today DermTech News Today Aptorum Group News Today RenovoRx News Today OncoCyte News Today Indaptus Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:LXRP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
